| Schizophrenia |
1 |
1 |
| Dopamine |
0 |
0.71 |
| Adverse Effects |
0 |
0.41 |
| Patient Safety |
0 |
0.35 |
| Blood |
0 |
0.2 |
| Dyspepsia |
0 |
0.2 |
| Europe |
0 |
0.2 |
| Nausea |
0 |
0.2 |
| Psychosis |
0 |
0.2 |
| Receptors |
0 |
0.2 |
| Alzheimer Disease |
0 |
0.15 |
| Constipation |
0 |
0.15 |
| Gastroesophageal Reflux Disease |
0 |
0.15 |
| Xerostomia |
0 |
0.14 |
| Agitation |
0 |
0.1 |
| Antipsychotics |
0 |
0.1 |
| Biomedical Technology |
0 |
0.1 |
| Face |
0 |
0.1 |
| Gamma aminobutyric acid |
0 |
0.1 |
| Hand |
0 |
0.1 |
| Hospital |
0 |
0.1 |
| Mental Illness |
0 |
0.1 |
| Mouth |
0 |
0.1 |
| New York |
0 |
0.1 |
| Psychosomatic Disorder |
0 |
0.1 |
| Psychotherapy |
0 |
0.1 |
| ADHD |
0 |
0.08 |
| Biologic Therapy |
0 |
0.08 |
| Bipolar Disorder |
0 |
0.08 |
| Dentistry and Oral Health |
0 |
0.08 |
| Headache |
0 |
0.08 |
| Healthcare and Medical Technology |
0 |
0.08 |